Compare EOG Resources Inc (EOG) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EOG Resources Inc vs Mesoblast Limited — how do they compare? EOG Resources Inc trades at $138.79 (market cap $73.22B), while Mesoblast Limited trades at $18.78 (market cap $2.31B). The key difference: EOG Resources Inc is far larger — about 31.7× Mesoblast Limited's market cap, and EOG Resources Inc pays a 2.97% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| EOG | MESO | |
|---|---|---|
Market Cap | $73.22B | $2.31B |
Sector | Energy | Technology |
52-Week High | $149.89 | $20.96 |
52-Week Low | $101.78 | $11.35 |
Enterprise Value | $77.68B | $2.32B |
Dividend Yield | 2.97% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EOG Resources trades at $139.12, up 0.8% on the day, with a bullish technical outlook supported by moving averages and key resistance at $140. The company maintains strong profitability with a 23.39% net income margin and has beaten earnings estimates for three consecutive quarters. Recent news highlights EOG's valuation discount and operational strength, with a consensus price target of $156.40 suggesting 12% upside.
EOG presents a compelling investment case with solid fundamentals, consistent earnings beats, and positive analyst sentiment, though risks include oil price volatility and elevated capital expenditures. The stock's current valuation below historical averages offers a margin of safety for long-term investors seeking exposure to a high-quality energy producer.
Mesoblast (MESO) trades at $19.12, up 14.22% with strong bullish technical signals from moving averages. The biotech company shows promising commercial progress with FDA-approved Ryoncil generating $115M annual revenue, though fundamentals reveal significant losses with a -144.33% net income margin and negative EBITDA of -$80.06M. Recent milestones include achieving Phase 3 trial targets for chronic low back pain and receiving a BLA filing number for heart failure treatment.
Investment outlook balances high growth potential from Mesoblast's cellular medicine platform against substantial financial losses and valuation concerns. The company's transition to commercial operations and pipeline advancements present opportunities, while persistent cash burn and negative profitability represent key risks requiring careful monitoring of upcoming clinical and regulatory catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
